J Neurol Surg B Skull Base 2025; 86(S 01): S1-S576
DOI: 10.1055/s-0045-1803333
Presentation Abstracts
Podium Presentations
Oral Presentations

Oncologic Outcomes in Nasopharyngeal Carcinoma: Influence of Treatment Modalities and Other Prognostic Factors

Authors

  • Mohammad Bilal Alsavaf

    1   Departments of Neurological Surgery and Otolaryngology—Head and Neck Surgery, The James Cancer Hospital at the Wexner Medical Center of The Ohio State University College of Medicine, Columbus, Ohio, United States
  • Matthew Marquardt

    2   The Ohio State University College of Medicine, Columbus, Ohio, United States
  • Moataz D. Abouammo

    3   Department of Otorhinolaryngology—Head and Neck Surgery, Tanta University, Tanta, Egypt
  • Dukagjin Blakaj

    4   Division of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Priyanka Bhateja

    5   Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Ricardo L. Carrau

    1   Departments of Neurological Surgery and Otolaryngology—Head and Neck Surgery, The James Cancer Hospital at the Wexner Medical Center of The Ohio State University College of Medicine, Columbus, Ohio, United States
  • Kyle K. VanKoevering

    6   Department of Otolaryngology—Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Marcelo Bonomi

    5   Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
 
 

    Introduction: Nasopharyngeal carcinoma (NPC) demonstrates distinct geographical distribution. However, radiation therapy represents the foundational treatment around the globe. Recently, induction chemotherapy plus chemoradiation (IC + CCRT) has been favored over chemoradiation plus adjuvant chemotherapy (CCRT + AC) due to its perceived better tolerance and earlier elimination of micro-metastases. This large retrospective study aimed to compare overall survival (OS) of different treatment regimens and identify prognostic factors.

    Method: We conducted a retrospective analysis of 155 NPC patients treated at a single tertiary institution during 2000 to 2022. Demographic, clinical, and survival data were extracted from medical records.

    Results: We included a total of 155 patients with an average age of 55 years of whom 73.5% are female. The cohort comprised 66, 21 and 13% of white, African American, and Asian, respectively. 36% of patients were current smokers, 30% were former smokers, and 34% were never smokers. One-third of patients were alcohol drinkers and 14% were marijuana users. Ninety patients were stained for P16 and 42% (38) were positive. EBV was tested in 126 patients finding that 54% (69) were positive. A total of 47 (30%), 46 (30%), and 57 (37%) patients received IC + CCRT, CCRT + AC, and only CCRT, respectively. Interestingly, EBV and p16 showed significant difference among races and WHO grades. Multivariate Cox analysis shows that smoking status and advanced tumor stage (IV) conferred substantially higher risk of recurrence. Female sex was a favorable prognostic factor for progression-free survival. Age, smoking status, and WHO grade were predictors for overall survival. Alcohol consumption was lower in survivors (mean: 2 vs. 5.5 standard cups; p = 0.035). Kaplan–Meier analysis identified female gender (p = 0.029), never smoking (p < 0.001), EBV positivity (p = 0.001), lower grade (p < 0.001), and earlier AJCC 8th stage (p < 0.001) as factors associated with superior OS. Also, increasing smoking index and age correlated with worse OS (hazard ratio: 1.01–1.02, p < 0.001; 1.02–1.06, p < 0.001, respectively). Race, alcohol, marijuana, p16 status, and treatment modalities (IC + CCRT vs. CCRT + AC vs. CCRT alone) did not impact OS.

    Conclusion: We identified several clinical and tumor-related prognostic factors for OS in NPC patients, including gender, smoking, EBV status, grade, and stage. However, none of the studied treatment regimens confer any OS advantage. Our data suggests that quitting or reducing smoking and reducing alcohol consumption improve OS. In comparison to most recent studies, we did not find an impact of p16 on overall survival ([Tables 1] [2] [3]).

    Zoom
    Zoom
    Zoom
    Zoom

    No conflict of interest has been declared by the author(s).

    Publication History

    Article published online:
    07 February 2025

    © 2025. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

     
    Zoom
    Zoom
    Zoom
    Zoom